Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance

Trial Profile

A Phase IB Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Dexamethasone
  • Indications Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2019 Results (n=12; as of 23 July 2019) presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 02 Dec 2019 According to an Amgen media release, results from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Dec. 7-10, 2019.
    • 16 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top